• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Human Growth Hormone Companies

    ID: MRFR/HC/5032-CR
    175 Pages
    Kinjoll Dey
    February 2021

    There are several pharmaceutical companies that produce and market growth hormone products. Growth hormone is a peptide hormone essential for the growth and development of tissues and organs in the human body. It is also known as somatotropin and is produced by the pituitary gland. When there is a deficiency of growth hormone in the body, it can lead to growth disorders and other medical conditions

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Human Growth Hormone Market Research Report - Global Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Human Growth Hormone Market


    Growth Hormone Key Companies*Disclaimer: List of key companies in no particular orderLatest Growth hormone Companies Update


    • June 2023: Pfizer Inc. and its partner, OPKO Health Inc., announced that the U.S. Food and Drug Administration (FDA) had authorized their medication for childhood growth hormone insufficiency. Pfizer's stock rose by less than 1 percent in premarket trade, while Opko Health's rose by more than 27 percent, after the FDA approved the medicine. Hormone therapy authorized for use in children as young as three years old and to be marketed under the brand name Ngenla. In August, it will hit shelves in the United States.




    • August 2023: Genexine, a publicly traded Korean biopharmaceutical company, released favorable top-line findings from a pivotal phase 3 study conducted in China. This study aims to assess the effectiveness and safety of eftansomatropin alfa, also known as GX-H9, Genexine's proprietary long-acting growth hormone, in children diagnosed with growth hormone deficiency. The once-weekly growth hormone developed by Genexine, in collaboration with I-Mab and Jumpcan, has demonstrated comparable efficacy to daily injections in a significant experiment conducted in China. These promising results position the companies to pursue regulatory clearance in the next year and make preparations for the subsequent sale of this medication.




    • September 2023: Ascendis Pharma A/S disclosed the findings of enliGHten, an open-label extension experiment conducted by the company. The trial aimed to assess the prolonged safety and effectiveness of TransCon hGH, administered once a week, as a therapeutic option for children and adolescents diagnosed with growth hormone deficiency (GHD). The enliGHten trial had a total of 298 individuals, with a mean age of 10.3 years. The participants enrolled in these clinical studies were administered a cumulative treatment duration of up to six years with TransCon hGH.


    List of Growth hormone Key companies in the market


    • Novo Nordisk A/S (Denmark)




    • Pfizer Inc. (US)




    • Ascendis Pharma A/S (Denmark)




    • EMD Serono (US)




    • Ferring B.V. (Switzerland‎)




    • Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China)




    • Sandoz International GmbH (Germany)




    • AnkeBio Co., Ltd (China)




    • Ipsen Pharma (France)




    • Genentech (US)